When the subjects were grouped according to MS status and divided into subgroups according to the particular components of MS, a trend in increasing serum FGF21 level accompanying increased numbers of MS-related disorders was noticed (P for trend < 0.01; Figure 2). The gene discussed is FGF21; the disease is myeloid sarcoma.